A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
Le Tourneau, Christophe, Delord, Jean-Pierre, Kotecki, Nuria, Borcoman, Edith, Gomez-Roca, Carlos, Hescot, Ségolène, Jungels, Christiane, Vincent-Salomon, Anne, Cockenpot, Vincent, Eberst, Lauriane, Molé, Audrey, Jdey, Wael, Bono, Françoise, Trochon-Joseph, Véronique, Toussaint, Hélène, Zandanel, Christelle, Adamiec, Olga, de Beaumont, Olivier, Cassier, Philippe Alexandre
Published in British journal of cancer (10.11.2020)
Published in British journal of cancer (10.11.2020)
Get full text
Journal Article
Abstract A076: Phase I dose escalation study evaluating the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AsiDNA, a first-in-class DNA Repair Inhibitor, administered intravenously (IV) in patients with advanced solid tumors
Tourneau, Christophe Le, Delord, Jean-Pierre, Cassier, Philippe, Kotecki, Nuria, Borcoman, Edith, Hescot, Ségolène, Jungels, Christiane, Mole, Audrey, Toussaint, Hélène, Adamiec, Olga, Beaumont, Olivier de
Published in Molecular cancer therapeutics (01.12.2019)
Published in Molecular cancer therapeutics (01.12.2019)
Get full text
Journal Article